David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on PYC Therapeutics Limited. The associated price target was raised to A$5.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Martin PhD has given his Buy rating due to a combination of factors including the significantly strengthened balance sheet following PYC’s AU$600M equity raise, which was executed at a premium price and largely supported by new U.S. specialist life sciences funds. This capital raise not only exceeds his prior funding assumptions but also reduces future financing risk and supports a more robust development plan than previously modeled.
With this cash position, PYC is well funded to progress all four of its therapeutic programs, including advancing its lead asset PYC-003 through later-stage development while continuing to generate data across the broader portfolio. Martin also highlights recent encouraging updates for VP-001, which enhance the company’s probability of success and justify maintaining a constructive valuation outlook, thereby supporting his continued Buy recommendation on the stock.
In another report released on March 17, Bell Potter also maintained a Buy rating on the stock with a A$2.30 price target.
PYC’s price has also changed dramatically for the past six months – from A$0.895 to A$1.365, which is a 52.51% increase.